The Bilingual Advantage: Atomic Science meets Economic Exit
In an era where a Nature-level breakthrough can still result in a commercially stranded asset, the traditional boundaries between clinical development and market access have collapsed.
I founded Sur Access to solve a specific structural failure in the biotech ecosystem: the "Due Diligence Blind Spot". Generalist strategists often lack the technical depth to see the evidence gaps that lead to a 40% rNPV haircut in the new JCA/MFN reality.
Why Partner with an Independent SME?
Investors and drug developers don't need another generalist report; they need a Technical Architect who speaks the languages of the lab, the regulator, and the bank simultaneously.
- Scientific Rigor (The ETH Lens):
With a
PhD from ETH Zürich
in Computational Chemistry, I perform "Atomic Audits" of clinical protocols. I understand the molecular masterpiece of a new treatment at its core, allowing me to evaluate if a trial’s endpoints are scientifically robust enough to satisfy the most skeptical HTA authorities.
- Economic Strategy (The LSE Lens):
My training at the
London School of Economics (Cost-effectiveness in Health Care certification)
and
RAPS Regulatory Affairs certification
allows me to translate that science into a protected price floor. I quantify the "Value at Risk," ensuring that your clinical strategy is, in fact, a pricing strategy.
- Local Precision, Global Impact: Based in the Geneva Life Sciences Hub, I leverage my location at the crossroads of global finance and European regulation. While my strategy is global, my execution is informed by deep local expertise in premium markets like Switzerland and strategic gateways like Croatia.
Breaking the "McKinsey Gap"
Large consultancies are built for volume; Sur Access is built for surgical precision. When you partner with me, you aren't getting a junior analyst’s spreadsheet. You are getting an SME-led Stress Test of your most valuable assets.
I don't just "assess" your portfolio; I de-risk your clinical evidence lifecycle to ensure that your scientific breakthroughs achieve the "High Added Benefit" ratings and exit multiples they deserve.
